Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization

• Status: Active, not recruiting
• Trial end date: 2022-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Our overarching goal is to improve the outcomes of critically ill COVID-19 patients with or at risk for development of acute kidney injury (AKI). The objective of this study is to determine the role of a protocol to manage urine alkalization using a simple medication that has been used for a very long time, is safe, and without significant side-effects. We aim to determine the feasibility and safety of a urine alkalinization protocol for the prevention of AKI in patients testing positive for COVID-19.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: West Virginia University

Criteria

Inclusion Criteria:

• Confirmed COVID-19 positive

• Admission to ICU or step-down unit

• Age ≥ 18 years old

Exclusion Criteria:

• Stage 3 AKI by KDIGO criteria

• CKD stage 4-5

• Contraindications to Na bicarbonate therapy (e.g. met. alkalosis, severe heart failure)

• Urine pH > 7.0